Mcm Product Sales was Emergent BioSolutions’s largest revenue line in fiscal 2025, bringing in $456.70M of $742.90M (61%).
| Products and Services | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Product Sales, Net | — | — | — | — | ||||
| Product Sales | — | — | — | — | ||||
| Mcm Product Sales | — | $447.20M | $509.80M | $456.70M | ||||
| Cost Of Mcm Product Sales | $579.60M | — | — | — | ||||
| Commercial Product Sales | $386.60M | $497.30M | $398.90M | $226.10M | ||||
| All Other Revenues | — | $104.80M | $134.90M | $60.10M | ||||
| Services | $105.00M | — | — | — | ||||
| Contracts & Grants | $41.40M | — | — | — | ||||
| Amount Of Revenue Earned From Products Sold Or Services Provided Under The Terms Of A Contract, Including, But Not Limited To, Government Contracts & Grants | — | — | — | — | ||||
| Contract Development & Manufacturing Services | — | — | — | — | ||||
| Revenue Earned During The Period Arising From Manufacturing Sale Under The Terms Of A Contract | — | — | — | — | ||||
| Total | $1.11B | $1.05B | $1.04B | $742.90M |
Emergent BioSolutions brought in $742.90M from its three revenue lines in fiscal 2025, the year ended December 31, 2025. That was down 28.8% from $1.04B in fiscal 2024. Mcm Product Sales was the largest at $456.70M (61.5%), ahead of Commercial Product Sales at $226.10M (30.4%) and All Other Revenues at $60.10M (8.1%).
Compared with fiscal 2024, every revenue line above 2% of revenue shrank. Mcm Product Sales held up best, down 10.4% to $456.70M, and All Other Revenues fell the most, down 55.4% to $60.10M.
Emergent BioSolutions began breaking out Mcm Product Sales in fiscal 2023 and All Other Revenues in fiscal 2023. Emergent BioSolutions stopped reporting Cost Of Mcm Product Sales ($579.60M in fiscal 2022), Services ($105.00M in fiscal 2022) and Contracts & Grants ($41.40M in fiscal 2022) as separate revenue lines.
United States was Emergent BioSolutions’s largest region in fiscal 2025, bringing in $531.10M of $742.90M (71%).
| Geography | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $886.10M | $607.20M | $822.60M | $531.10M | ||||||
| U.S Government | — | — | — | — | ||||||
| U.S. Government | — | — | — | — | ||||||
| Non-U.S. Government | — | — | — | — | ||||||
| Canada | $148.60M | $224.20M | $140.40M | $75.00M | ||||||
| Other | $82.80M | $217.90M | $80.60M | $136.80M | ||||||
| Total | $1.12B | $1.05B | $1.04B | $742.90M |
Emergent BioSolutions brought in $742.90M from its three regions in fiscal 2025, the year ended December 31, 2025. That was down 28.8% from $1.04B in fiscal 2024. United States was the largest at $531.10M (71.5%), ahead of Other at $136.80M (18.4%) and Canada at $75.00M (10.1%).
Compared with fiscal 2024, Other grew fastest, up 69.7% to $136.80M, while Canada fell the most, down 46.6% to $75.00M. From fiscal 2022 to 2025, combined revenue from these regions fell from $1.12B to $742.90M, a compound annual decline of 12.7%. United States' share of the total fell from 79.3% to 71.5%.
Mcm Products was Emergent BioSolutions’s largest segment in fiscal 2025, bringing in $456.70M of $742.90M (61%).
| Segment | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Mcm Products | $447.20M | $509.80M | $456.70M | ||||||
| Commercial Products | $497.30M | $398.90M | $226.10M | ||||||
| Segment Of The Company Which Develops, Manufactures & Commercializes Vaccines And Antibody Therapies For Use Against Biological Agents That Are Potential Weapons Of Bioterrorism Or Biowarfare | — | — | — | ||||||
| Other | $104.80M | $134.90M | $60.10M | ||||||
| Segment Of The Company Which Develops Vaccines, Antibody Therapies & Technology Platforms For Use Against Infectious Diseases, Oncology, Autoimmune And Inflammatory Disorders And Other Medical Conditions That Have Resulted In Significant Unmet Or Underserved Public Health Needs | — | — | — | ||||||
| Total | $1.05B | $1.04B | $742.90M |
Emergent BioSolutions brought in $742.90M from its three segments in fiscal 2025, the year ended December 31, 2025. That was down 28.8% from $1.04B in fiscal 2024. Mcm Products was the largest at $456.70M (61.5%), ahead of Commercial Products at $226.10M (30.4%) and Other at $60.10M (8.1%).
Compared with fiscal 2024, every segment above 2% of revenue shrank. Mcm Products held up best, down 10.4% to $456.70M, and Other fell the most, down 55.4% to $60.10M. From fiscal 2023 to 2025, combined revenue from these segments fell from $1.05B to $742.90M, a compound annual decline of 15.9%. Mcm Products' share of the total rose from 42.6% to 61.5%.
Emergent BioSolutions (EBS) reports its revenue by products and services, by geography and by segment. In fiscal 2025, Mcm Product Sales was its largest revenue line, bringing in $456.70M (61.5% of the total), followed by Commercial Product Sales at $226.10M (30.4%).
Mcm Product Sales was Emergent BioSolutions' largest revenue line in fiscal 2025, bringing in $456.70M, or 61.5% of the $742.90M total across its three revenue lines.
United States was Emergent BioSolutions' largest region in fiscal 2025, bringing in $531.10M, or 71.5% of the $742.90M total across its three regions.
Mcm Products was Emergent BioSolutions' largest segment in fiscal 2025, bringing in $456.70M, or 61.5% of the $742.90M total across its three segments.
Among Emergent BioSolutions' regions that make up at least 2% of revenue, Other grew fastest in fiscal 2025, up 69.7% from $80.60M to $136.80M.
Every figure comes from Emergent BioSolutions' annual financial filings, as reported. Each line keeps the name Emergent BioSolutions gives it, and years follow its fiscal calendar.
Emergent BioSolutions' revenue by products and services goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.